PortalPublikationenIntroducing the first polymer-free leflunomide eluting stent...

Introducing the first polymer-free leflunomide eluting stent.

Standard

Introducing the first polymer-free leflunomide eluting stent. / Deuse, Tobias; Erben, Reinhold G; Ikeno, Fumiaki; Behnisch, Boris; Böger, Rainer; Connolly, Andrew J; Reichenspurner, Hermann; Bergow, Claudia; Pelletier, Marc P; Robbins, Robert C; Schrepfer, Sonja.

in: ATHEROSCLEROSIS, Jahrgang 200, Nr. 1, 1, 2008, S. 126-134.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Deuse, T, Erben, RG, Ikeno, F, Behnisch, B, Böger, R, Connolly, AJ, Reichenspurner, H, Bergow, C, Pelletier, MP, Robbins, RC & Schrepfer, S 2008, 'Introducing the first polymer-free leflunomide eluting stent.', ATHEROSCLEROSIS, Jg. 200, Nr. 1, 1, S. 126-134. <http://www.ncbi.nlm.nih.gov/pubmed/18295768?dopt=Citation>

APA

Deuse, T., Erben, R. G., Ikeno, F., Behnisch, B., Böger, R., Connolly, A. J., Reichenspurner, H., Bergow, C., Pelletier, M. P., Robbins, R. C., & Schrepfer, S. (2008). Introducing the first polymer-free leflunomide eluting stent. ATHEROSCLEROSIS, 200(1), 126-134. [1]. http://www.ncbi.nlm.nih.gov/pubmed/18295768?dopt=Citation

Vancouver

Deuse T, Erben RG, Ikeno F, Behnisch B, Böger R, Connolly AJ et al. Introducing the first polymer-free leflunomide eluting stent. ATHEROSCLEROSIS. 2008;200(1):126-134. 1.

Bibtex

@article{1f1c94ff11b241c3845fb76ef8c93a1e,
title = "Introducing the first polymer-free leflunomide eluting stent.",
abstract = "BACKGROUND: We here describe the pharmacological characteristic, in vivo efficacy, and in vitro mechanisms of a polymer-free leflunomide eluting stent in comparison to its rapamycin-coated equivalent. METHODS: Stents were coated with 40 mM solutions of leflunomide (L) or rapamycin (R) or were left uncoated (BM). Neointima formation was assessed 6 weeks after implantation into Sprague Dawley rats by optical coherence tomographies (OCT) and histopathology. In vitro proliferation assays were performed using isolated endothelial and smooth-muscle-cells from Sprague Dawley rats to investigate the cell-specific pharmacokinetic effect of leflunomide and rapamycin. RESULTS: HPLC-based drug release kinetics revealed a similar profile with 90% of the drug being released after 12.1+/-0.2 (L) and 13.0+/-0.2 days (R). After 6 weeks, OCTs showed that in-stent luminal obliteration was less for the coated stents (L:12.0+/-9.4%, R:13.3+/-13.1%) when compared to identical bare metal stents (BM:26.4+/-4.7%; p",
author = "Tobias Deuse and Erben, {Reinhold G} and Fumiaki Ikeno and Boris Behnisch and Rainer B{\"o}ger and Connolly, {Andrew J} and Hermann Reichenspurner and Claudia Bergow and Pelletier, {Marc P} and Robbins, {Robert C} and Sonja Schrepfer",
year = "2008",
language = "Deutsch",
volume = "200",
pages = "126--134",
journal = "ATHEROSCLEROSIS",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Introducing the first polymer-free leflunomide eluting stent.

AU - Deuse, Tobias

AU - Erben, Reinhold G

AU - Ikeno, Fumiaki

AU - Behnisch, Boris

AU - Böger, Rainer

AU - Connolly, Andrew J

AU - Reichenspurner, Hermann

AU - Bergow, Claudia

AU - Pelletier, Marc P

AU - Robbins, Robert C

AU - Schrepfer, Sonja

PY - 2008

Y1 - 2008

N2 - BACKGROUND: We here describe the pharmacological characteristic, in vivo efficacy, and in vitro mechanisms of a polymer-free leflunomide eluting stent in comparison to its rapamycin-coated equivalent. METHODS: Stents were coated with 40 mM solutions of leflunomide (L) or rapamycin (R) or were left uncoated (BM). Neointima formation was assessed 6 weeks after implantation into Sprague Dawley rats by optical coherence tomographies (OCT) and histopathology. In vitro proliferation assays were performed using isolated endothelial and smooth-muscle-cells from Sprague Dawley rats to investigate the cell-specific pharmacokinetic effect of leflunomide and rapamycin. RESULTS: HPLC-based drug release kinetics revealed a similar profile with 90% of the drug being released after 12.1+/-0.2 (L) and 13.0+/-0.2 days (R). After 6 weeks, OCTs showed that in-stent luminal obliteration was less for the coated stents (L:12.0+/-9.4%, R:13.3+/-13.1%) when compared to identical bare metal stents (BM:26.4+/-4.7%; p

AB - BACKGROUND: We here describe the pharmacological characteristic, in vivo efficacy, and in vitro mechanisms of a polymer-free leflunomide eluting stent in comparison to its rapamycin-coated equivalent. METHODS: Stents were coated with 40 mM solutions of leflunomide (L) or rapamycin (R) or were left uncoated (BM). Neointima formation was assessed 6 weeks after implantation into Sprague Dawley rats by optical coherence tomographies (OCT) and histopathology. In vitro proliferation assays were performed using isolated endothelial and smooth-muscle-cells from Sprague Dawley rats to investigate the cell-specific pharmacokinetic effect of leflunomide and rapamycin. RESULTS: HPLC-based drug release kinetics revealed a similar profile with 90% of the drug being released after 12.1+/-0.2 (L) and 13.0+/-0.2 days (R). After 6 weeks, OCTs showed that in-stent luminal obliteration was less for the coated stents (L:12.0+/-9.4%, R:13.3+/-13.1%) when compared to identical bare metal stents (BM:26.4+/-4.7%; p

M3 - SCORING: Zeitschriftenaufsatz

VL - 200

SP - 126

EP - 134

JO - ATHEROSCLEROSIS

JF - ATHEROSCLEROSIS

SN - 0021-9150

IS - 1

M1 - 1

ER -